Data are presented as n (%), unless otherwise stated. IPF: idiopathic pulmonary fibrosis; CAPACITY: Clinical Studies Assessing Pirfenidone in IPF: Research of Efficacy and Safety Outcomes. ^#: n=345; ^¶: n=347; ⁺: based on the Cox-proportional hazard model; ^§: log-rank test (pirfenidone 2403 mg·day⁻¹ versus placebo); ^ƒ: assessed by the investigator, who remained blinded to treatment assignment; ^##: defined as the time from randomisation until 28 days after the last dose of study drug. Reproduced from [22] with permission from the publisher.